PHARMACY

MPS&A’s pharmacy management system EnterpriseRx earns industry accolades

BY Michael Johnsen

LIVONIA, Mich. — McKesson Pharmacy Systems & Automation on Friday announced that EnterpriseRx — its cloud-based, centrally hosted pharmacy management system — earned top honors as a Category Leader in the 2013 Best in KLAS: Software and Services report. KLAS, an independent healthcare research organization, reserves the Category Leader designation for vendors that lead select market segments with software solutions designed to help healthcare professionals provide better care for their patients.

“We are proud to earn KLAS’s recognition for the outstanding technology that EnterpriseRx offers the health system market,” stated Emilie Ray, VP  and general manager, outpatient, MPS&A. “We believe our pharmacy management system’s strong ranking in this industry is a reflection of our commitment to provide world-class pharmacy solutions to pharmacists, physicians and patients.”

EnterpriseRx is designed to allow pharmacists to run a patient-centered business and to make a pronounced difference in the way that pharmacies are traditionally run. The system increases operational efficiencies behind the counter so that pharmacists can spend more time on clinical programs such as adherence, medication therapy management and distribution of specialty medications.

“EnterpriseRx has set its self apart in operational efficiency and support of clinical programs, but our next focus is on connectivity between providers throughout the health system,” said Nathan Mott, president MPS&A. “With the backing of McKesson and our involvement in the CommonWell Health Alliance, we are looking forward to being at the forefront of an initiative that connects pharmacy to the continuum of care.”

 

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Lupin approved for generic Monodox, Cipro

BY Ryan Chavis

MUMBAI and BALTIMORE — Lupin on Thursday announced that it received final approval from the Food and Drug Administration for its doxycycline capsules USP, 50 mg, 75 mg and 100 mg, which is the generic version of Aqua Pharmaceuticals’ Monodox capsules. The drug is used to treat infections caused by various microorganisms and as an adjunctive therapy in severe acne, according to the company.

The company also received FDA approval for its ciprofloxacin for oral suspension 5 g/100 mL (250 mg/5 mL) and 10 g/100 mL (500-mg/5-mL), a generic form of Cipro for oral suspension from Bayer HealthCare Pharmaceuticals. The drug is used for the treatment of infections caused by susceptible isolates of the designated microorganisms in various conditions and patient populations, the company said.

Monodox capsules had annual sales in the United States of 180.6 million for the year ending December 2013, according to IMS MAT data; Cipro oral suspension had sales of $8.6 millon.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Study: Participation in diabetes education associated with greater ability to self-manage

BY Michael Johnsen

LIVERPOOL, England — Study results announced Thursday by Novo Nordisk and collaborative partners found that participation in diabetes education is associated with a greater sense of well-being and the ability to self-manage diabetes.

However, more than three-quarters of people with diabetes in the United Kingdom (78%) have never attended a diabetes education program, and family members are rarely included (79%). Additionally, only 14% of healthcare professionals say that all their patients with diabetes are offered structured diabetes education classes.

The findings of the DAWN2 study show that more than a quarter (26%) of people with diabetes experience diabetes-related distress. Yet family members also experience distress, with around half (47%) worrying about low blood sugar (hypoglycaemic) events, and nearly 1-in-10 (9%) family members likely having depression.

The DAWN2 global study of diabetes was conducted among 15,000 people in 17 countries, including 900 people with diabetes, family members, caregivers and healthcare professionals in the United Kingdom. 

“DAWN2 reveals the burden on families of those living with diabetes. Families are worried about their loved one’s future, fearful about aspects such as hypoglycaemia, and keen to help when it comes to self-management," said Simon O’Neill, director of Health Intelligence at Diabetes UK and DAWN2 steering committee member. "We must take a person-centered approach to diabetes care that includes all those involved — the individual, their family network and the healthcare professional community. We need to work together to create a plan of care based on the person’s individual needs."

In response to these findings, a national action plan has been launched to help improve diabetes care in the United Kingdom. The DAWN2 action plan has been developed by an independent, multidisciplinary group with the support of Novo Nordisk, and will provide innovative tools and resources to people living with and caring for diabetes, as part of a three-year program. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?